EMA Authorised: Buprenorphine Neuraxpharm (buprenorphine hydrochloride) — Neuraxpharm Pharmaceuticals S.L.

View source ↗

Summary

The EMA authorised Buprenorphine Neuraxpharm (buprenorphine hydrochloride) for opioid-related disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• Buprenorphine Neuraxpharm (buprenorphine hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Opioid-Related Disorders. MAH: Neuraxpharm Pharmaceuticals S.L.. Decision date: 16/05/2025